Updated:
Intarcia Therapeutics
Intarcia Therapeutics was founded to address the chronic-disease adherence problem by creating a long-acting, implantable delivery system.
Intarcia Therapeutics
Intarcia Therapeutics was founded to address the chronic-disease adherence problem by creating a long-acting, implantable delivery system. The company's flagship technology, the Medici Drug Delivery System, is a miniature osmotic pump that can deliver a steady dose of a therapeutic agent for up to one year. Intarcia applied this platform to type 2 diabetes with ITCA 650 (exenatide), which showed superior glycemic control in Phase III trials (per the New England Journal of Medicine, 2015). The firm raised nearly $1B in equity from investors including New Enterprise Associates, Amgen Ventures, and Venrock (per PitchBook, 2020 archive). Despite the clinical success, the FDA issued a Complete Response Letter in 2017 citing concerns over manufacturing quality, and a second rejection in 2020. Intarcia filed for Chapter 11 bankruptcy in September 2020 and was acquired by an affiliate of its secured lender, Deerfield Management, for $150M (per FiercePharma, 2020). Following the bankruptcy, the Medici platform's potential extends beyond diabetes to other chronic conditions where adherence is a barrier—such as HIV prevention, opioid addiction, and cardiovascular disease. The asset remains under the control of Deerfield Management as of 2025, with no public development pipeline disclosed since the exenatide program was shelved. Intarcia's structural differentiator was its focus on a physical drug-device combination rather than a purely pharmaceutical product, introducing orthogonal regulatory and manufacturing risks. The overlap between its clinical promise (real-world adherence for millions of patients) and its regulatory failure (FDA manufacturing concerns) makes it a case study in how drug-device hybrids bear the liabilities of both categories. No successor entity has announced resumed clinical development.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Sector focus
Frequently asked questions
What was Intarcia Therapeutics' lead product candidate?
Intarcia's lead product was ITCA 650, a once-yearly subdermal mini-pump delivering exenatide—a GLP-1 receptor agonist—for type 2 diabetes. It demonstrated non-inferiority to daily injections in Phase III trials but failed FDA approval due to manufacturing quality concerns (per the FDA, 2017).
Why did the FDA reject Intarcia's application?
The FDA issued two Complete Response Letters—in 2017 and 2020—citing insufficient evidence of manufacturing quality, specifically relating to stability and sterility of the implantable device. No efficacy or safety concerns with the drug itself were noted (per the FDA's official CRLs, 2017, 2020).
Who acquired Intarcia's assets after its bankruptcy?
Deerfield Management, a healthcare investment firm and Intarcia's secured lender, acquired the company's assets for approximately $150 million through a credit bid in 2020 (per FiercePharma, 2020). Deerfield has not publicly disclosed plans for the Medici Drug Delivery System since.
What is the Medici Drug Delivery System?
The Medici Drug Delivery System is a matchstick-sized osmotic mini-pump implanted under the skin that delivers a steady, continuous dose of a therapeutic agent over 12 months. Developed by Intarcia, it was designed to improve adherence for chronic diseases requiring daily medication (per Intarcia's SEC filings, 2015).
What other therapeutic areas could the Medici platform target?
Beyond diabetes, the Medici platform could theoretically be applied to HIV pre-exposure prophylaxis, opioid-use disorder, cardiovascular disease, and metabolic conditions. The technology enables zero-pill adherence for chronic diseases where daily oral therapy is a barrier. No new clinical programs have been announced since Intarcia's bankruptcy.
How much capital did Intarcia raise before its bankruptcy?
Intarcia raised nearly $1 billion in equity from institutional investors including New Enterprise Associates, Amgen Ventures, Venrock, and Gallileo Partners, among others (per PitchBook, 2020 archive). The company also borrowed from Deerfield Management and other lenders.
Did Intarcia have operations outside of Boston?
Public records indicate Intarcia was headquartered in Boston, MA. No additional offices have been disclosed. The company's clinical trials were conducted across multiple sites in the United States (per ClinicalTrials.gov, 2017).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: